This presentation will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology, and summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into clinical trials and the clinical laboratory. The establishment of proteogenomics represents an important component towards implementation of broader precision medicine efforts in cancer and beyond. See also: Nat Rev Clin Oncol. 2019, 16(4):256-268 (PMID: 30487530) and Cell. 2021, 184(7):1661-1670 (PMID: 33798439)